A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ovarian Neoplasms
- Endometrial Neoplasms
- Uterine Cervical Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Neoplasms
- Pancreatic Neoplasm
- Colorectal Neoplasms
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- HonorHealth · Scottsdale, AZ
California · 1
- University of California, San Diego (UCSD) - Moores Cancer Center · La Jolla, CA
Michigan · 1
- South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, MI
New York · 3
- NYU Langone Health - Long Island · Mineola, NY
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, NY
- New York University (NYU) Clinical Cancer Center · New York, NY
Ohio · 1
- The Ohio State University (OSU) Wexner Medical Center · Columbus, OH
Texas · 1
- The University of Texas - MD Anderson Cancer Center · Houston, TX
Utah · 1
- START Mountain Region · West Valley City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.